SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hollander Anna)
 

Sökning: WFRF:(Hollander Anna) > Soluble CD163 predi...

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma

Nikkarinen, Anna (författare)
Uppsala University,Uppsala universitet,Cancerprecisionsmedicin,Ingrid Glimelius
Lokhande, Lavanya (författare)
Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments
Amini, Rose-Marie (författare)
Uppsala University,Uppsala universitet,Cancerimmunterapi,Rose-Marie Amini
visa fler...
Jerkeman, Mats (författare)
Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Onkologi övergripande,Institutionen för kliniska vetenskaper, Lund,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Oncology corporate,Department of Clinical Sciences, Lund
Porwit, Anna (författare)
Lund University,Lunds universitet,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine
Molin, Daniel, 1969- (författare)
Uppsala University,Uppsala universitet,Cancerimmunterapi,Gunilla Enblad
Enblad, Gunilla (författare)
Uppsala University,Uppsala universitet,Cancerimmunterapi,Gunilla Enblad
Kolstad, Arne (författare)
Innlandet Hosp Trust Div Gjovik, Dept Oncol, Lillehammer, Norway.,Innlandet Hospital Trust
Raety, Riikka (författare)
Helsinki Univ Hosp, Comprehens Canc Ctr, Dept Hematol, Helsinki, Finland.,Helsinki University Central Hospital
Hutchings, Martin (författare)
Rigshosp, Dept Haematol, Copenhagen, Denmark.,Copenhagen University Hospital
Weibull, Caroline E. (författare)
Karolinska Institutet,Karolinska Institute
Hollander, Peter (författare)
Uppsala University,Uppsala universitet,Cancerimmunterapi,Rose-Marie Amini
Ek, Sara (författare)
Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments
Glimelius, Ingrid, 1975- (författare)
Uppsala University,Karolinska Institute,Uppsala universitet,Cancerprecisionsmedicin,Karolinska Inst, Dept Med, Div Clin Epidemiol, Stockholm, Sweden.,Ingrid Glimelius
visa färre...
 (creator_code:org_t)
American Society of Hematology, 2023
2023
Engelska.
Ingår i: Blood Advances. - : American Society of Hematology. - 2473-9529 .- 2473-9537. ; 7:18, s. 5304-5313
Relaterad länk:
http://dx.doi.org/10... (free)
visa fler...
https://urn.kb.se/re...
https://doi.org/10.1...
https://lup.lub.lu.s...
http://kipublication...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • The outcome for patients with mantle cell lymphoma (MCL) has drastically improved with new treatments directed toward the tumor immune microenvironment, where macrophages play an important role. In MCL, the presence of M2 macrophages defined by CD163 expression in diagnostic biopsies has been associated with a worse prognosis. An alternative way to assess the abundance of M2 macrophages is by measuring the level of soluble CD163 in serum (sCD163). We aimed to investigate the prognostic value of sCD163 in 131 patients with MCL. We found that high sCD163 at diagnosis was associated with shorter progression-free survival (PFS) and shorter overall survival (OS) in 81 patients who were newly diagnosed and subsequently treated with chemoimmunotherapy. The same was seen in a cohort of 50 patients with relapsed MCL that were mainly treated within the phase 2 Philemon-trial with rituximab, ibrutinib, and lenalidomide. In patients who were newly diagnosed and had low levels of sCD163, 5-year survival was 97%. There was a moderate correlation between sCD163 and tissue CD163. The association with a poor prognosis was independent of MCL international prognostic index, Ki67, p53 status, and blastoid morphology, as assessed in a multivariable Cox proportional hazards model. In this study, high sCD163 was associated with both shorter PFS and shorter OS, showing that high levels of the M2 macrophage marker sCD163 is an independent negative prognostic factor in MCL, both in the chemoimmunotherapy and ibrutinib/lenalidomide era. In addition, low sCD163 levels identify patients with MCL with a very good prognosis.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy